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Normally, cyclin interacts with cyclin-dependent kinase 
(CDK) to form a cyclin-CDK complex, which promotes 
cell cycle progression, whereas cyclin-dependent kinase 
inhibitor (CDKI) molecules inhibit the formation of cyc-
lin-CDK complex, arresting cell cycle. Terminal erythro-
poiesis is closely coordinated with cell cycle exit, which is 
regulated by cyclins, CDKs, and CDKIs [1]. In the global 
transcriptome of human terminal erythropoiesis [2], 
p19INK4d is expressed highly, and its expression is signifi-
cantly up-regulated during human terminal erythropoie-
sis. However, the roles of p19INK4d in terminal erythro-
poiesis are still unknown.
As reported in our article recently published in Blood 
entitled “Unexpected roles for p19INK4d in posttranscrip-
tional regulation of GATA1 and modulation of human 
terminal erythropoiesis” [3], we demonstrated what roles 
p19INK4d plays in human terminal erythropoiesis. We 
found that, in the erythropoietin-induced, CD34-positive 
hematopoietic stem cell (HSC) differentiation system, 
knockdown of p19INK4d delays terminal erythroid differ-
entiation, inhibits erythroblast growth due to increased 
apoptosis, and leads to the generation of abnormally 
nucleated late-stage erythroblasts. Unexpectedly, knock-
down of p19INK4d did not affect cell cycle, and these func-
tions caused by p19INK4d knockdown were via decreasing 
levels of GATA-binding protein 1 (GATA1). Furthermore, 
we found that p19INK4d modulates GATA1 protein levels 
through a novel pathway, the phosphatidylethanolamine-
binding protein 1 (PEBP1)-phosphorylated extracellular 
signal-regulated kinase (pERK)-heat shock 70  kDa pro-
tein (HSP70)-GATA1 pathway [3].
As a classical CDKI member, p19INK4d has been shown 
to inhibit the formation of cyclin D-CDK4/6 complex, 
arresting cell cycle in the G0/G1 phase [4]. p19INK4d was 
often induced to inhibit the proliferation of many kinds 
of tumor cells, such as T cell acute lymphoblast leuke-
mia cells and lung cancer H1299 cells [4, 5]. Additionally, 
deletion of p19INK4d leads to the development of many 
tumors, including osteosarcomas [6] and anterior lobe 
tumors [7]. p19INK4d is also involved in HSC quiescence, 
megakaryocyte differentiation, and granulocytic differen-
tiation, which are closely associated with cell cycle arrest 
[8–10]. However, as shown in our study, p19INK4d played 
important roles independent of cell cycle regulation, and 
the lack of cell cycle change was probably due to the com-
pensatory up-regulation of p18INK4c following p19INK4d 
knockdown. Our findings provide greater understanding 
of the role that CDKIs play in cell cycle regulation.
In conclusion, our study revealed the cell cycle-inde-
pendent roles of p19INK4d in human terminal eryth-
ropoiesis via a novel PEBP1-pERK-HSP70-GATA1 
pathway. These findings will likely improve understand-
ing of disordered erythropoiesis, including thalassemia, 
myelodysplastic syndrome, and congenital dyserythro-
poietic anemia, and guide future studies that focus on 
CDKIs.
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